rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Examine Urine and Bladder Tissues From Egyptian Male Patients and Controls Using Whole Genomic Sequencing Techniques and 16S rRNA. The Aim is to Elucidate Role of Microbiota in Bladder Cancer.
Status: Recruiting

Microbes inhabiting the urinary tract that are playing an important role in maintenance of health and the development of diseases and bladder cancer. There is correlation between initiation of bladder cancer and microbes. Urine and bladder tissues from healthy individuals and patients with bladder cancer were analyzed using 16S rRNA sequencing, results show abundant phylum. Next-generation sequencing technologies will be applied with whole genomic and 16S ribosomal RNA gene sequencing for microbiota profiling in urine and bladder tissue of male healthy individuals and patients with bladder cancer. Results will lead to prevention, diagnosis, and new treatment strategies for bladder cancer.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Adult men above 18 years, Diagnosed of carcinoma of the bladder with imaging ultrasonography and/ or computerized tomography, and urine cytology. Confirmed bladder cancer either during diagnostic cystoscopy, previous pathology, or pathological examination of the biopsy specimens.  Exclusion Criteria:  - Previous radiotherapy to the bladder or to adjacent organ. Previous intravesical instillation immunotherapy with bacillus Calmette-Guérin (BCG), or intravesical instillation of chemotherapeutics. Previous neoadjuvant chemotherapy. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: Male - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Bladder cancer:  Samples: Total number of studied samples: The study will explore the microbiota in urine and in tissue samples, so every patient with bladder cancer will give (2 samples). The control group will give urine sample ( one samble).  Group I: Non-muscle invasive bladder cancer,16 patients, 16 for bladder tissue, and 16 for urine samples. Total 32 samples. (The study will explore the microbiota in urine and in tissue samples, so every patient with bladder cancer will give (2 samples). The control group will give urine sample (1 samble).  Group II: Muscle invasive bladder cancer, 11 patients. 22 samples 11 for bladder tissue and 11 for urine samples obtained from the same patients. Group III: 11 Normal adults: urine samples from serves as control group of the study.  Total number of participants is 38 individuals. - SamplingMethod: Non-Probability Sample
Correlation Between Muscle Strength and Thickness in Critically Ill Patients
Status: Recruiting

Mechanical ventilation (MV) is associated with adverse outcomes in ventilated patients, and impact of MV-induced diaphragm changes are still unclear.

The objective of this prospective observational study is to assess muscle thickness and strength, specifically in limb muscles such as the quadriceps, among critically ill patients who undergo extended mechanical ventilation during their Intensive Care Unit (ICU) stay.

The primary inquiries this study seeks to address are:

Is there an association between muscle thickness and strength in the limbs of critically ill patients undergoing prolonged MV?
How much thickness and strength variation can be expected in respiratory and limb muscles in critically ill patients undergoing prolonged MV?

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age ≥ 18 years; Intubated patients on mechanical ventilation presumably for 48 hours; Informed consent  Exclusion Criteria:  Contraindication (absolute or relative) to assessment: acute bleeding, multiple fractures or trauma, spinal instability; Hemodynamic instability during assessment; ICU admission due to thoracic surgery, including lung transplant patients; History of preexisting neuromuscular diseases; History of preexisting functional impairment; Pheripheral Neural disease; Cervical spine injury; - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients admitted to the Intensive Care Unit (ICU) who are expected to need mechanical ventilation for at least 48 hours following ARDS. - SamplingMethod: Non-Probability Sample
The Use of Artificial Intelligence (AI) for Gait Analysis
Status: Not yet recruiting

The main purpose of this study will be to assess the consistency and reliability of measurements made using the Vicon three-plane gait analysis device (Vicon Motion Capture System Ltd, Oxford, UK) and a mobile application based on image recognition technology with the help of artificial intelligence.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  healthy people aged 20-25 years  Exclusion Criteria:  orthopaedic disease neurological disease rheumatological disease pain in lower limbs in the last 6 months pain in lumbar spine in the last 6 months surgeries of lower limbs in the last 6 months surgeries of spine in the last 6 months musculoskeletal injuries in the lower limbs in the last 6 months musculoskeletal injuries in the lumbar spine in the last 6 months overweight and obesity, determined on the basis of the BMI value - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 20 Years - MaximumAge: 25 Years - StdAgeList: Adult - StudyPopulation: Students of the Academy of Physical Education and Sport in Gdańsk, - SamplingMethod: Non-Probability Sample
Kinesio Taping Versus Interferential Current Therapy in Treating Knee Osteoarthritis
Status: Not yet recruiting

The purpose of this study will be to compare the combined effect of using Kinesio taping versus interferential current with an exercise program on knee pain, function, knee range of motion, knee muscle strength, and functional mobility in chronic knee osteoarthritis.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Forty-eight Male and female patients aged between 40 and 65 years old were diagnosed clinically and radiologically as knee osteoarthritis grade mild and moderate chronic knee osteoarthritis. BMI ranges between 20 and 32 kg/m2. Knee OA grades 1 and 2 are based on Kellgren and Lawrence's grades. Narrowing of joint space, definite osteophytes. Unilateral knee osteoarthritis.  Knee pain for most days of the prior month, in addition to at least 3 of the following:  Crepitus on active joint motion Morning stiffness less than 30 minutes duration Age older than 50 years Bony enlargement of the knee on examination Bony tenderness of the knee on examination No palpable warmth.  Exclusion Criteria:  Patients having the following conditions will be excluded from the study:  Comorbidities such as (rheumatoid arthritis, cancer, osteoporosis, and joint infection). Previous surgery for knee OA. BMI more than 33 kg/m2. Suffering from polyarticular disease. Severe mechanical deformity (diaphyseal Varus deformity of 4° and valgus of 16°). Previous arthroscopy within the last year. Systemic autoimmune rheumatoid disease (connective tissue disease and systemic necrotizing vasculitis). - HealthyVolunteers: No - Gender: All - MinimumAge: 40 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult
"Comparing Methotrexate Usage Techniques to Prevent Proliferative Vitreoretinopaty After Retinal Detachment Vitrectomy"
Status: Recruiting

This clinical trial, involving participants with rhegmatogenous retinal detachment, aims to compare Methotrexate Usage Techniques in preventing Proliferative Vitreoretinopathy (PVR) after vitrectomy. The study will evaluate the development of PVR, retinal detachment recurrence, and improvement in visual acuity. Participants will undergo retinal detachment surgery using the vitrectomy technique and will be divided into two groups. One group will receive Methotrexate infusion during surgery, while the other will receive repeated Methotrexate injections post-surgery. The researcher will analyze and compare outcomes between the two groups.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Rhegmatogenous Retinal Detachment  Exclusion Criteria:  Presence of proliferative vitreoretinopathy grade C, previous retinal detachment surgery in the same eye, penetrating ocular trauma, Presence of intraocular foreign bodies, previous glaucoma filtration surgery, allergy to methotrexate, and pregnant and lactating women. - HealthyVolunteers: No - Gender: All - MinimumAge: 20 Years - MaximumAge: 70 Years - StdAgeList: Adult, Older Adult
Testing C-Raven, a Virtual Tobacco Cessation Intervention, in the Community
Status: Not yet recruiting

To inform a future randomized trial of a virtual counselor led computer delivered intervention for tobacco cessation augmented with community health worker (CHW) support and navigation to lung cancer screening in low-income housing units in Baltimore, the investigators propose to collect data on intervention acceptability and feasibility among individuals in public housing as well as feedback on use of shared decision making when referring for low-dose chest CT (LDCT).

The investigators will conduct a feasibility pilot study of a virtual counselor plus community health worker intervention. With a sample of participants from public housing units (N=15), the investigators will collect data on feasibility of recruitment, intervention engagement and completion, and short-term smoking cessation outcomes. Individuals will be assessed at baseline, 1 month and 3 months. At the end of three months, the investigators will conduct follow up interviews with a subset of pilot participants to collect qualitative data on intervention acceptability. Based on this information, the investigators will make iterative improvements to the combined intervention.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age 50 or older Current tobacco use with >100 cigarettes smoked in their lifetime English speaking (intervention currently in English only and housing units are in largely English-speaking neighborhoods) Considering smoking cessation Planning to remain in current housing unit for 6 months  Exclusion Criteria:  Current use of pharmacological treatment for tobacco cessation Contraindication to nicotine replacement therapy Current engagement in formal smoking cessation program Major cognitive or psychiatric impairment Severe hearing impairment Investigator discretion - HealthyVolunteers: No - Gender: All - MinimumAge: 50 Years - StdAgeList: Adult, Older Adult
Thyroid and Cortisol Hormone Response to Sepsis
Status: Not yet recruiting

Thyroid and cortisol hormone response to sepsis

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  The study will include Adults (≥18 years), both genders septic patients admitted to critical care unit  Exclusion Criteria:  thyroid disease hypopituitarism Addison disease Cushing syndrome) - Gender: All - MinimumAge: 18 Years - MaximumAge: 100 Years - StdAgeList: Adult, Older Adult - StudyPopulation: include Adults (≥18 years), both genders, admitted to critical care unit with sepsis  Exclusion patient with Previous diagnosis of endocrinal changes (thyroid dysfunction , hypopituitarism, Addison disease, Cushing syndrome) - SamplingMethod: Non-Probability Sample
Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor
Status: Not yet recruiting

This study will assess the safety and efficacy of multiple-dose of STSP-0601 for the treatment of bleeding episodes in hemophilia A or B patients with inhibitor.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  18 ≤age≤70 years of age,male. Hemophilia A or B patients. A bleeding event requiring treatment occurred (Only applicable to the on-demand treatment stage). Peak historical inhibitor titer ≥ 5 BU and apositive inhibitor test when enrolled. There were at least 3 bleeding events that requiring treatment occurred in the past 6 months before screening (Only applicable to the on-demand treatment stage). Establish proper venous access. Agree to use adequate contraception to avoid pregnancy. Provide signed informed consent.  Exclusion Criteria:  Have any coagulation disorder other than hemophilia. Plan to receive prophylactic treatment of coagulation factor during the trail. Patients plan to receive Emicizumab during the trial. Patients received anticoagulant or antifibrinolytic therapy 7 days before enrollment or plan to receive these drugs during the trial.Patients received anticoagulation therapy (such as coagulation factor replacement therapy, prothrombin complex, plasma, etc.) 7 days before enrollment. Have a history of arterial and/or venous thrombotic events. Platelet <100×10 9/L. Hemoglobin<90g/L. Severe liver or kidney disease. Severe bleeding event occurred within 4 weeks before enrollment. Accepted major operation or blood transfusion within 4 weeks before enrollment. Have a known allergy to STSP-0601. Participate in other clinical research within 4 weeks before enrollment(except for participating in prothrombin complex, FVII, FVIIa, FVIII, FIX trails). Patients not suitable for the trail according to the judgment of the investigators. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 70 Years - StdAgeList: Adult, Older Adult
Internal Bracing Following ACL Reconstruction
Status: Recruiting

The purpose of this study is to assess Anterior Cruciate Ligament (ACL) healing through analyzing clinical, radiographic, functional and patient-reported outcomes following ACL reconstruction with quadriceps graft with and without internal bracing.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  • History of ACL injury indicated for isolated reconstruction, without concomitant ligament reconstruction or repair, cartilage repair procedure, or osteotomy.  Exclusion Criteria:  Patients who underwent concomitant ligament reconstruction or repair, cartilage repair procedure, or osteotomy. History of blood-borne diseases including HIV, HBV, HCV, HTLV, and syphilis. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Oral Bioavailability of a New Formulation of Pterostilbene Cocrystal in Comparison With Its Free Form (BIOPTERO2)
Status: Not yet recruiting

The goal of this interventional study is to to evaluate the oral bioavailability of the crystallized form of pterostilbene (ccPT) compared to its commercial free base form (pterostilbene (PT) in healthy volunteers. The main question it aims to answer are:

• Do the crystallized forms of pterostilbene (ccPT) using two different encapsulation methods exhibit greater bioavailability than its commercial free base form (PT)?

Participants will attend to four visits: a preselection visit (V0), a visit for the first postprandial study (V1), a visit for the second postprandial study (V2) after one-week washing period and a visit for the third postprandial study (V3) after another one week washing period.

Researchers will analyze the three postprandial assays to determine which type of ccPT encapsulation provides the highest bioavailability compared to the commercial free base form (PT).

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Men and women between 18 and 65 years of age. Sign the informed consent form. Know how to read, write and speak Spanish  Exclusion Criteria:  Take supplements or multivitamin supplements or phytotherapeutic products (especially infusions) that interfere with the treatment under study up to 30 days before the start of the study. Be lacto-vegetarian, lacto-ovo-vegetarian, or vegan. Present intolerances and/or food allergies related to pterostilbene or the excipients. Be a smoker. Having received antibiotic treatment up to 30 days before the start of the study. Present values of body mass index ≤ 18kg/m^2 or ≥ 35 kg/m^2. Present some chronic disease with clinical manifestations: coronary heart disease, cardiovascular disease, diabetes, celiac disease, Crohn's disease, chronic kidney disease, cancer, autoimmune diseases (such as fibromyalgia), respiratory and/or gastrointestinal diseases that may compromise the absorption of the compound. Clinical history of anemia. Being pregnant or intending to became pregnant. Be in breastfeeding period. Being unable to follow the study guidelines. Participate in or have participated in a clinical trial or nutritional intervention study in the last 30 days before inclusion in the study. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: Male - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult
Predictive Utility of a Short-term Improvement in Objectively Measured Physical Activity in Rheumatoid Arthritis (PUSIPA)
Status: Recruiting

SUMMARY Background: Several studies have shown physical activity (PA) to be inversely correlated to disease activity in rheumatoid arthritis (RA) patients. However, it is unclear whether improved PA leads to lower disease activity or if low disease activity predicts improved PA in rheumatoid arthritis patients. Furthermore, it is unknown how fibromyalgia (FM) affects this interaction.

Objective(s): Our primary objective will be to compare the effect of an immediate improvement in physical activity after one week on the proportion of RA patients achieving low disease activity after 12 weeks of biological treatment. Furthermore, we will explore whether the presence of concomitant FM affects this clinical response (i.e., interaction between FM status and PA response).

Design: A prospective cohort study in the form of a target-trial attempting to address a causal question comparing the outcome among the participants with an immediate improvement in physical activity, relative to individuals without.

Setting and patients: Biologically naive RA patients initiating biological treatment are consecutively enrolled. PA is quantified by accelerometry one week prior to, one week after, and after 3 months of biological treatment.

Sample size: 100 RA patients starting biological therapy is planned enrolled in the study.

Measurements: RA patients will be divided into two groups depending on their improvement in physical activity after onset of biological treatment. The percentage of time spent in moderate-to-vigorously physical activity (MVPA) i.e., the percentage of time a patient is in motion [walking, running, bicycling, or swimming] is measured prior to, one week, and approximately 3 months after biological treatment onset, respectively. The MVPA ratio (MVPA After biological treatment/MVPA Before biological treatment) will divide patients enabling a contrast between two groups: Those with high improvement considering MVPA (after 1 week; the upper tertile of MVPA ratio of the sample) and those without. Treatment response (achieving a disease activity score < 3.2) after approximately 3 months from baseline will be analyzed as the contrast between groups.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients with RA (> 18 years of age) who are to be treated with a biological agent and who can read and understand Danish  Exclusion Criteria:  Patients who are physically impaired (patients depending on assistance devices for walking), pregnancy, patients who have received corticosteroids two weeks prior to and during the period of the movement measurement, and patients who by virtue of illiteracy or cognitive impairment are unable to complete the questionnaire. - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients with RA (> 18 years of age) who are to be treated with a biological agent. - SamplingMethod: Probability Sample
text4FATHER R21: Social Media - Efficacy Trial
Status: Not yet recruiting

This project will be the first to examine the efficacy of a text messaging intervention designed to recruit first-time fathers-to-be using social media across the U.S. to become involved during pregnancy through two months of postnatal age to support infant, mother, and father well-being.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Aged ≥18 years Live in the U.S. Speak English Mother gestational age at enrollment less than 25 weeks First-time father-to-be Willing/able to receive texts.  Exclusion Criteria:  Individuals who are minors Do not speak English Unable to provide informed consent Not a first-time father Not willing/unable to receive texts In the past 12 months, any safety concern reported between father-to-be and the mother-to-be, including report of any physical, emotional, sexual harm, threatening behaviors, police involvement, restraining or protective order - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
The Effect of an Individually Adapted Lumbosacral Orthosis on Plantar Pressure and Balance
Status: Not yet recruiting

The aim of this study is to examine the effect of steel underwire lumbosacral orthosis adapted to the individual by the prosthetist orthotist on pain, comfort, plantar pressure, static and dynamic balance in individuals with low back pain.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Between the ages of 18-65, One or more recurrent low back pain during the last 12 months,-At least 6 points on the Oswestry Disability Index, Negative straight leg raising test result, Not having any lower extremity injuries in the last 6 months, No history of recent trauma or infection  Exclusion Criteria:  Neurological symptoms due to nerve root compression One-sided leg pain more severe than lower back pain, pain in feet and toes shooting pain, numbness in the same area, paresthesia, Disease that causes neurological sequelae (stroke, traumatic brain injury, Parkinson's, Those who have had it (such as multiple sclerosis), Presence of malignancy, - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult
PrognostICate- Study:Prognostication of ICU- and Ventilator- Days Over the Next Years Until 2040
Status: Not yet recruiting

The Objective of our retrospective multicenter- study is to forecast ICU length of stay (ICULOS) and length of mechanical ventilation (LOMV) in ICU patients of different groups (regarding gender, age group, medical vs surgical admission) worldwide for the next years up to the year of 2040 using statistical forecasting models and historical, national and international ICU databases and population databases.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  All patients admitted to an ICU between the years 2005-2023  Exclusion Criteria:  Patients without ICU admission or ICU admission < 4 hours - HealthyVolunteers: No - Gender: All - MinimumAge: 1 Day - MaximumAge: 120 Years - StdAgeList: Child, Adult, Older Adult - StudyPopulation: ICU patients worldwide - SamplingMethod: Probability Sample